Akebia Therapeutics (AKBA) Capital Expenditures (2013 - 2026)
Akebia Therapeutics (AKBA) reported Capital Expenditures of $62000.0 for Q1 2026, up 244.44% year-over-year from $18000.0 in Q1 2025, and down 11.43% quarter-over-quarter from $70000.0 in Q4 2025.
Akebia Therapeutics (AKBA) Capital Expenditures (2013 - 2026) Analysis & Trends
Akebia Therapeutics (AKBA) has 13 years of Capital Expenditures data on file, last reported at $62000.0 in Q1 2026.
- Capital Expenditures for Q1 2026 came in at $62000.0, up 244.44% year-over-year; the trailing twelve-month figure through Mar 2026 was $335000.0 (up 556.86% YoY), and the FY2025 annual result was $291000.0, up 781.82% from the prior year.
- Capital Expenditures retreated to $62000.0 in Q1 2026 per AKBA's latest filing, from $70000.0 in the prior quarter.
- Over five years, Capital Expenditures peaked at $126000.0 in Q2 2025 and troughed at $2000.0 in Q3 2024.
- A 4-year average of $55555.6 and a median of $62000.0 in 2026 frame the typical range for Capital Expenditures.
- The sharpest annual moves came in 2022 and 2025: Capital Expenditures surged 93.22% in 2022, then jumped 3750.0% in 2025.
- A 4-year view of Capital Expenditures shows it stood at $114000.0 in 2022, then sank by 98.25% to $2000.0 in 2024, then surged by 3400.0% to $70000.0 in 2025, then declined by 11.43% to $62000.0 in 2026.
- Business Quant data shows AKBA's Capital Expenditures at $62000.0 in Q1 2026, $70000.0 in Q4 2025, and $77000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn | 168.00 Mn |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn | 110.00 Mn |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn | 100.80 Mn |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn | - |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn | 9.10 Mn |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn | 51.00 Mn |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn | 4.09 Mn |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn | 8.83 Mn |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn | 2.04 Mn |
| 10 | Akebia Therapeutics | 243.23 Mn | 80.63 Mn | 41.25 Mn | 62,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 62,000.00 |
| Mar 31, 2026 | 62,000.00 |
| Dec 31, 2025 | 70,000.00 |
| Dec 31, 2025 | 70,000.00 |
| Sep 30, 2025 | 77,000.00 |
| Sep 30, 2025 | 77,000.00 |
| Jun 30, 2025 | 126,000.00 |
| Jun 30, 2025 | 126,000.00 |
| Mar 31, 2025 | 18,000.00 |
| Mar 31, 2025 | 18,000.00 |
| Dec 31, 2024 | 2,000.00 |
| Dec 31, 2024 | 2,000.00 |
| Sep 30, 2024 | 2,000.00 |
| Sep 30, 2024 | 2,000.00 |
| Jun 30, 2024 | 29,000.00 |
| Jun 30, 2024 | 29,000.00 |
| Mar 31, 2022 | 114,000.00 |
| Mar 31, 2022 | 114,000.00 |
| Mar 31, 2021 | 59,000.00 |
| Mar 31, 2021 | 59,000.00 |